LBH and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, LBH was underexpressed in more indolent, late-onset acute myeloid leukemia (LAML/AML, −1.1-fold in TCGA; −2.5-fold in Oncomine) (Fig. 1C; Fig. 1F.i; and Fig. S1A.xix), and in slow-growing, chronic myeloid leukemia (CML, −2.47) and chronic adult T-cell leukemia/lymphoma (ATLL, −2.27) (Table S3).